PeptideSkincare
Peptide Science

SNAP-8 Peptide (Acetyl Octapeptide-3): What It Is, How It Works and What the Evidence Shows

By · Published October 10, 2026 · 12 min read

Start with our pillar guide: Peptide Ingredients in Skincare: Signal, Carrier, Neurotransmitter and Enzyme-Inhibitor Peptides Explained, or browse all Peptide Science articles.

Direct answer: The SNAP-8 peptide is the trade name for acetyl octapeptide-3, an 8-amino-acid relative of Argireline marketed to soften expression lines by interfering with the SNARE complex nerves use to signal muscles. No independent human trial has tested SNAP-8 alone; the only human data come from 2 industry-linked, multi-ingredient patch studies. Evidence: early / preliminary.

Key takeaways

  • SNAP-8's official INCI name is acetyl octapeptide-3. The EU's CosIng database lists its functions as humectant and skin conditioning, not anti-wrinkle (CosIng).
  • It is Argireline's 6-amino-acid sequence plus 2 more (Ala-Asp). No head-to-head trial shows that this makes it stronger.
  • The only verified concentration in published human research is 0.03%, inside a dissolving microneedle patch with 2 other actives (Shin et al., 2024).
  • Neither human study can isolate SNAP-8's effect, and the patch makers were involved in both.
  • ClinicalTrials.gov shows 0 registered studies of SNAP-8 or acetyl octapeptide-3 as of October 10, 2026 (ClinicalTrials.gov).

SNAP-8 belongs to the "neurotransmitter-inhibiting" family of cosmetic peptides. A 2009 review counted this family as 1 of 4 broad classes, alongside signal, carrier and enzyme-inhibitor peptides (Gorouhi & Maibach, 2009). Our guide to peptide ingredients in skincare explains each class and its evidence.

What is the SNAP-8 peptide?

SNAP-8 is a trade name owned by the ingredient supplier Lipotec. Product labels use the INCI name, acetyl octapeptide-3. CosIng, the European Commission's cosmetic ingredient database, describes it as the "reaction product of acetic acid and Octapeptide-3" (CosIng).

CosIng lists only 2 functions: humectant (it helps hold water) and skin conditioning. It lists no anti-wrinkle or muscle-relaxing function. That doesn't prove SNAP-8 does nothing for wrinkles, but the anti-wrinkle claim comes from marketing, not from the regulatory listing.

The sequence

A 2024 study reported the full sequence as Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 (Shin et al., 2024). "Ac" is an acetyl cap on one end and "NH2" marks amidation of the other end. Both are common tweaks that make peptides more stable.

Argireline (acetyl hexapeptide-8) is Ac-EEMQRR-NH2, or Glu-Glu-Met-Gln-Arg-Arg (Blanes-Mira et al., 2002). SNAP-8 has the same first 6 amino acids, with alanine and aspartic acid added to the end.

How is the SNAP-8 peptide supposed to work?

To make a muscle contract, a nerve releases acetylcholine. That release depends on the SNARE complex, a set of proteins that zip together so the vesicle holding acetylcholine can fuse with the nerve cell membrane. One of those proteins is SNAP-25, which gives SNAP-8 its name.

Argireline was designed by copying a short stretch of SNAP-25's N-terminal end (Wang et al., 2013). The idea is that this fragment competes with the real protein and destabilizes the complex. In the original lab work, Argireline interfered with SNARE complex formation and stability. It inhibited neurotransmitter release with potency similar to botulinum toxin A's but much lower efficacy (Blanes-Mira et al., 2002). It acted at similar doses but had a much weaker maximum effect. Evidence: lab only, from authors involved in developing the peptide.

SNAP-8 is sold on the same mechanism. A 2026 review groups "Snap-8 (Acetyl Octapeptide-3)" with other synthetic peptides that mimic botulinum toxin A's mechanism (Kassem et al., 2026). However, none of the sources we could verify include an indexed, peer-reviewed lab study of SNAP-8's own effect on the SNARE complex. The mechanism is inferred from Argireline's design.

Does "longer" mean "stronger"?

Brands often call SNAP-8 an upgraded Argireline because its 2 extra amino acids mimic a longer stretch of SNAP-25. That's a reasonable hypothesis, but it is a marketing inference, not a tested result.

For the parent peptide, see our guide to what Argireline does.

We found no head-to-head trial of SNAP-8 vs Argireline in PubMed or Europe PMC. Lipotec has efficacy figures for SNAP-8, but they come from manufacturer testing that hasn't been published in indexed peer-reviewed journals, so we don't repeat them here.

Does the SNAP-8 peptide work in human studies?

We found exactly 2 indexed human studies that include SNAP-8. Both tested multi-ingredient microneedle patches, not a SNAP-8 cream or serum, and both had industry involvement.

Study 1: Shin et al., 2024 (eye-area patch, placebo-controlled)

  • Product: a dissolving hyaluronic acid (HA) microneedle patch containing 5% ascorbyl glucoside (a vitamin C derivative), 4% sodium cyclic lysophosphatidic acid, 0.03% SNAP-8 and 90% HA.
  • Design: 24 healthy subjects wore the active patch on one eye area and an HA-only placebo patch on the other, overnight, for 28 days.
  • Results: compared with placebo, the active side improved in eye wrinkles, transepidermal water loss (TEWL, a measure of water escaping through the skin barrier), elasticity and lifting. No adverse effects were reported.
  • Funding: the authors were employed by Raphas Co., the patch maker, and the study was "supported by Raphas Co." (Shin et al., 2024).

Evidence: early / preliminary. The placebo patch controls for the microneedles and HA but not for the vitamin C derivative or lysophosphatidic acid. So you can't tell which of the 3 actives, if any, drove the result.

Study 2: Avcil et al., 2020 (12-week patch study)

  • Product: HA microneedle patches containing an arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts.
  • Design: a monocentric (single-site) 12-week trial on the outer eye corners and inner forearm. The abstract describes no control arm and doesn't report the sample size.
  • Results: fine lines fell 25.8%, hydration rose 15.4%, skin density rose 14.2% and thickness rose 12.9%.
  • Affiliations: the authors were from Imperial Bioscience, Dermatest and Raphas (Avcil et al., 2020).

Evidence: early / preliminary. The patches contained 5 named actives plus microneedles, and the study describes no control, so none of these changes can be attributed to SNAP-8.

How this compares with Argireline's evidence

Argireline's evidence is thin, but it includes a randomized, placebo-controlled human trial. In that trial, 60 Chinese subjects were randomized 3:1 to Argireline or placebo, applied twice daily around the eyes for 4 weeks. The Argireline group reached 48.9% subjective total anti-wrinkle efficacy, compared with 0% for placebo, and skin roughness parameters dropped (p<0.01). The abstract doesn't report the funder (Wang et al., 2013). Evidence: limited.

SNAP-8 has no comparable stand-alone trial. Retinol, by contrast, has stronger evidence. In a vehicle-controlled study of 36 elderly participants, 0.4% retinol used for 24 weeks reduced fine wrinkle scores by 1.64, compared with 0.08 for vehicle (Kafi et al., 2007). That result sits within a much larger body of retinoid research (Mukherjee et al., 2006).

Even topical studies of combined Botox-mimetic peptides tend to be small. In the 2026 Kassem study, 15 analyzed participants used a formula with Argireline, Syn-Ake and other ingredients but not SNAP-8. Their average time before needing another neurotoxin injection rose from 13.5 to 22.3 weeks. There was no control group, the study was investigator-initiated, and Lileger Ltd supplied the products (Kassem et al., 2026). Evidence: early / preliminary, and not about SNAP-8.

Does SNAP-8 absorb into skin?

Whether SNAP-8 absorbs into skin is the biggest open question. We found no SNAP-8-specific skin penetration data in the indexed literature we reviewed, so everything below is inferred from Argireline and general peptide research.

  • Argireline penetrates poorly. One study found poor skin permeation and attributed it to Argireline's large molecular weight, its hydrophilicity (it's water-loving) and its zwitterionic nature (it carries both positive and negative charges) (Lim et al., 2018). SNAP-8 is 2 amino acids longer and has the same charged core, so there's no obvious reason to expect it to penetrate better. That is our inference, not a measured result.
  • The base formula matters. In porcine (pig) skin, water-rich emulsions (W/O/W and O/W) delivered more Argireline than an oil-rich W/O emulsion (Hoppel et al., 2015). Evidence: lab / animal only.
  • Reaching the target is uncertain. A 2025 review concluded that it remains unclear whether Argireline can reach neuromuscular junctions, where nerves meet muscle (Zdrada-Nowak et al., 2025).
  • Most anti-wrinkle peptides share this problem. A 2022 review found that most are poor candidates for skin permeation and may not reach their targets at effective concentrations. The review listed microneedles, nanocarriers, chemical modification and iontophoresis (a small electric current) as ways to improve delivery (Mortazavi & Moghimi, 2022).

This helps explain why both human studies used microneedle patches, which physically push ingredients past the outer skin barrier. See also our explainer on whether peptides actually absorb into skin.

What concentration of SNAP-8 peptide works?

The only concentration we can verify from published human research is 0.03% SNAP-8, in the Shin patch (Shin et al., 2024). The Avcil abstract doesn't state a concentration (Avcil et al., 2020).

There is no dose-response data, because no study has compared SNAP-8 concentrations to see whether more works better. The percentage on a product page often refers to a supplier solution rather than pure peptide. No peer-reviewed evidence links any percentage to a given result, so don't choose a product based on the number on the front label.

For context, the original Argireline work used a 10% oil-in-water emulsion (Blanes-Mira et al., 2002). That was a different peptide in a different format, so it says nothing about SNAP-8 dosing.

What can you pair the SNAP-8 peptide with?

No interaction studies exist for SNAP-8. No published research has tested it with retinoids, vitamin C, niacinamide, acids or other peptides, so the guidance below is reasoning, not evidence.

  • Peptides are generally low-irritation, so layering SNAP-8 with a retinoid or niacinamide is unlikely to cause problems on its own. No data; reasoning only.
  • Don't make SNAP-8 your main anti-aging step. Retinoids have far more human evidence for wrinkles (Kafi et al., 2007; Mukherjee et al., 2006). Treat a SNAP-8 product as an optional extra.
  • Water-based formulas may deliver more. Based on the Argireline porcine-skin data, a water-rich serum or lotion is a reasonable choice over a heavy oil-based balm (Hoppel et al., 2015). That is an inference from a different peptide.
  • Introduce one new product at a time so you can tell what caused any reaction.

Is it safe to buy SNAP-8 powder or inject it?

In skincare and "biohacking" communities, some people buy SNAP-8 as a "research use" powder from peptide vendors and mix it into homemade serums. Some report that their forehead feels tighter or moves less, while others saw nothing after 1 to 2 months. Anecdotes like these can't separate a real effect from expectation, lighting or a hydrating base.

The DIY route has 3 problems:

  • No quality standard. Vendor powders labeled "for research use" are not cosmetic-grade ingredients. Their purity, identity and contamination are unverified.
  • No formulation. The base formula changes how much peptide reaches the skin (Hoppel et al., 2015). A powder stirred into a store-bought serum has unknown stability and delivery.
  • No safety data at DIY doses. The only cytotoxicity data we found are for Argireline. In cultured human cells, including skin fibroblasts, Argireline had a dose-dependent antiproliferative effect. Significant cytotoxicity appeared only at concentrations 18 to 10,000 times higher than those of the chemotherapy drug doxorubicin. The authors also noted the lack of independent cytotoxicity data beyond the manufacturer's (Grosicki et al., 2014). We found no comparable data for SNAP-8.

Injecting SNAP-8 has never been studied in humans. There are no safety, dosing or sterility data, and vendor powders aren't made to injectable standards. We don't recommend it. For injectable treatment of expression lines, talk to a board-certified dermatologist or another licensed clinician about approved neurotoxins.

Does SNAP-8 have side effects?

Neither human study reported adverse effects (Shin et al., 2024; Avcil et al., 2020). However, one study had 24 subjects and the other didn't report its sample size, which is too little data to rule out uncommon reactions.

Be more cautious if you have reactive or allergy-prone skin, are pregnant or breastfeeding (there are no data either way), or are planning a procedure. In those cases, ask your clinician before adding new actives.

Where the evidence stops

  • No stand-alone human trial. Every indexed human study combined SNAP-8 with other actives and microneedles, so its own contribution is unknown.
  • No independent replication. Patch manufacturers were involved in both studies, and Lipotec's efficacy data aren't published in indexed peer-reviewed journals.
  • No head-to-head with Argireline. The claim that "8 amino acids beat 6" hasn't been tested.
  • No penetration data. It's unknown whether SNAP-8 in a serum reaches the nerve endings it targets.
  • No dose-response or interaction data. We don't know the right concentration or how SNAP-8 behaves with retinoids, acids or other peptides.
  • No registered trials. ClinicalTrials.gov listed 0 studies as of October 10, 2026 (ClinicalTrials.gov).

We'll update this page if an independent, controlled trial of SNAP-8 is published.

FAQ

Is SNAP-8 better than Argireline? We don't know. SNAP-8 has Argireline's sequence plus 2 extra amino acids, but no published trial has compared them directly. Argireline has a 60-person randomized placebo-controlled trial (Wang et al., 2013), while SNAP-8 has no stand-alone trial. Based on the published evidence, Argireline is the better-studied peptide.

Can you inject SNAP-8? No human study has tested injected SNAP-8, so there are no safety or dosing data. Vendor "research" powders aren't made to injectable or sterile standards. For injectable treatment of expression lines, see a licensed clinician about approved neurotoxins.

How long until SNAP-8 shows results? There's no timeline for SNAP-8 used on its own. The 2 multi-ingredient patch studies measured changes at 28 days (Shin et al., 2024) and 12 weeks (Avcil et al., 2020). The Argireline trial ran 4 weeks (Wang et al., 2013). If you see no change after about 3 months of consistent use, the product probably isn't doing much.

Can SNAP-8 cause breakouts? Neither human study reported adverse effects, but both were small. People in skincare communities occasionally report small breakouts after starting a SNAP-8 product. The base formula, other ingredients or contaminants in unregulated powders could cause these just as easily as the peptide. Introduce the product on its own, and stop using it if irritation or breakouts persist.

Is SNAP-8 a Botox alternative? It's grouped with peptides that mimic botulinum toxin A's mechanism (Kassem et al., 2026). However, even its parent peptide, Argireline, showed much lower efficacy than the toxin in lab work (Blanes-Mira et al., 2002). No human data show SNAP-8 producing neurotoxin-like results.

What concentration of SNAP-8 should a product contain? The only verified figure in published human research is 0.03%, in a microneedle patch with other actives (Shin et al., 2024). No study has compared concentrations, so a higher number on the label doesn't mean a better product.

References

  1. Shin JY, et al. [Dissolving hyaluronic acid microneedle patch with ascorbyl glucoside, sodium cyclic lysophosphatidic acid and 0.03% SNAP-8; eye-area wrinkles.] Annals of Dermatology. 2024. n=24 healthy subjects; active vs HA-only placebo patch on contralateral eye areas, overnight, 28 days; authors employed by and study supported by Raphas Co. https://pubmed.ncbi.nlm.nih.gov/39082657/
  2. Avcil M, et al. [Hyaluronic acid microneedle patches with bioactive peptides including acetyl octapeptide-3; monocentric clinical study.] Journal of Cosmetic Dermatology. 2020. Monocentric, 12 weeks; n not reported in the abstract; no control arm described; industry-affiliated authors. https://pubmed.ncbi.nlm.nih.gov/31134751/
  3. Kassem R, et al. [Topical Botox-mimetic peptide formula and neurotoxin reinjection interval.] Journal of Cosmetic Dermatology. 2026. 15 analyzed; no control group; investigator-initiated; products supplied by Lileger Ltd; formula did not contain SNAP-8. doi:10.1111/jocd.71183. https://europepmc.org/article/PMC/PMC13584236
  4. Blanes-Mira C, et al. [Rational design of a synthetic hexapeptide (Argireline) with antiwrinkle activity.] International Journal of Cosmetic Science. 2002. In vitro plus 30-day human emulsion test; n not reported in the abstract; authors involved in the peptide's development. https://pubmed.ncbi.nlm.nih.gov/18498523/
  5. Wang Y, et al. [Anti-wrinkle efficacy of Argireline in Chinese subjects.] American Journal of Clinical Dermatology. 2013. Randomized placebo-controlled, n=60 (3:1), 4 weeks. https://pubmed.ncbi.nlm.nih.gov/23417317/
  6. Lim SH, et al. [Skin permeation of Argireline.] Scientific Reports. 2018. Lab permeation study. https://pubmed.ncbi.nlm.nih.gov/29371611/
  7. Hoppel M, et al. [Delivery of acetyl hexapeptide-8 from different emulsion types into porcine skin.] 2015. Ex vivo porcine skin. https://pubmed.ncbi.nlm.nih.gov/25497319/
  8. Zdrada-Nowak, et al. [Review of acetyl hexapeptide-8.] 2025. Narrative review. https://pubmed.ncbi.nlm.nih.gov/40565185/
  9. Grosicki M, et al. [Cytotoxicity of Argireline in human cell lines.] Acta Biochimica Polonica. 2014. In vitro (HEK-293, IMR-32, human skin fibroblasts). https://pubmed.ncbi.nlm.nih.gov/24644551/
  10. Mortazavi SM, Moghimi HR. [Skin permeability of anti-wrinkle peptides.] International Journal of Cosmetic Science. 2022. Review. https://pubmed.ncbi.nlm.nih.gov/35302659/
  11. Gorouhi F, Maibach HI. [Topical peptides and aged skin.] 2009. Review. https://pubmed.ncbi.nlm.nih.gov/19570099/
  12. Kafi R, et al. [Topical retinol and naturally aged skin.] 2007. Vehicle-controlled, n=36 elderly participants, 24 weeks. https://pubmed.ncbi.nlm.nih.gov/17515510/
  13. Mukherjee S, et al. [Retinoids in the treatment of skin aging.] 2006. Review. https://pubmed.ncbi.nlm.nih.gov/18046911/
  14. European Commission. CosIng cosmetic ingredient database: entry for ACETYL OCTAPEPTIDE-3 (functions: humectant, skin conditioning). https://ec.europa.eu/growth/tools-databases/cosing/
  15. ClinicalTrials.gov. Search for "acetyl octapeptide-3" OR SNAP-8; 0 registered studies, searched October 10, 2026. https://clinicaltrials.gov/

Bracketed text describes each study's topic. See the linked record for the full published title.

Disclosure: This article contains no affiliate links, and no brand or ingredient supplier paid for or reviewed it. It summarizes published research for general education and is not medical advice. Talk to a dermatologist or other licensed clinician before starting a treatment, especially an injectable one. SNAP-8 is a trade name of Lipotec. We don't reproduce manufacturer efficacy data that haven't been published in indexed peer-reviewed journals.

For educational purposes only; not medical advice. See our disclaimer and research method.